Prosight Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.13M Sell
37,000
-61,080
-62% -$15.5M 1.77% 19
2026
Q2
$29.5M Buy
98,080
+22,080
+29% +$6.66M 5.09% 7
2026
Q1
$25.1M Buy
76,000
+58,891
+344% +$20M 4.12% 10
2025
Q4
$6.8M Buy
+17,109
New +$7.57M 1.41% 23
2022
Q2
– Sell
-22,704
Closed -$3.71M – 26
2022
Q1
$3.71M Sell
22,704
-9,203
-29% -$1.4M 2.39% 12
2021
Q4
$5.41M Buy
+31,907
New +$5.93M 3.24% 13

Other funds holding ALNY

Prosight Management's ALNY Position: Q3 2026 in Review

Prosight Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 62% in Q3 2026, selling an estimated $15.5M and leaving 37,000 shares worth $9.13M. The position accounts for 1.77% of the portfolio, ranked #19.

Prosight Management first reported a position in ALNY in Q4 2021 and has held it in 6 quarters since. The position peaked at $29.5M in Q2 2026. 729 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Prosight Management held 37,000 shares of Alnylam Pharmaceuticals worth $9.13M as of Q3 2026.
  • Prosight Management sold 61,080 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $15.5M.
  • Alnylam Pharmaceuticals made up 1.77% of Prosight Management's portfolio in Q3 2026, its #19 holding.
  • Prosight Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
  • Prosight Management's Alnylam Pharmaceuticals position peaked at $29.5M in Q2 2026.
  • 729 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Prosight Management's 13F filing for Q3 2026, filed 13 Nov 2026.